Quest EDI is an HL7 report. The OBX segment in the HL7 data file reports substances and their results. Technically the OBX is referred to as the “Observation Segment.” Some OBX segments, specific to the data provided by Quest, report things like Hair Source, Specimen information, Patient Phone Number, etc.
Some of these Observed values do not fit into the standard reporting paradigm for substances; lab screens report Negative or Positive and OBX segments that report confirmations provide a numeric value detected.
DTNet now takes some OBX values and reports them in the Lab Notes.
For example, consider the following 3 OBX segments:
OBX|2|TX|^^^70025^SPECIMEN SUBMITTED||HAIR RECD ON URINE CCF
OBX|3|TX|^^^70026^TEST(S) ORDERED||VERIFY ACCOUNT AND PANEL TO RUN
These observations will report in the Lab Notes’ section of the data record as:
HAIR SOURCE: HEAD
SPECIMEN SUBMITTED: HAIR RECD ON URINE CCF
TEST(S) ORDERED: VERIFY ACCOUNT AND PANEL TO RUN
The personnel data entry module has been reorganized; input has been economized so the screen is visually easy to navigate, the essential data elements are highlighted and the different data sections are easily identified. DTNet’s employee/patient records provide a lot of information, however, not every subscriber needs to keep track of it all. The data entry fields have been grouped together into logical sections and each section can be easily opened when the user needs to manage those components.
The DOT (U.S. Department of Transportation) added four substances and removed one from the drug testing panel. It expanded the panel to include four “semi-synthetic” opioid drugs (hydrocodone, hydromorphone, oxycodone and oxymorphone) and removed methylenedioxyamphetamine (MDA). The changes to the DOT rules take effect on January 1, 2018.
The Federal Drug Panel includes the following substances:
- Phencyclidine (PCP)
- MDMA: commonly known as ecstasy (E)
- MDA: Methylenedioxyamphetamine
- 6-AM (Heroin)
Your Federal Drug Panel should include each drug separately. If you’re getting data directly from the lab and the result is negative for Hydrocodone/Hydromorphone, the lab may simply report both together as “Hydrocodone/Hydromorphone: Negative.”
If, however, one or both are specifically detected, the lab may report, for example:
- Hydrocodone/Hydromorphone: Positive
- Hydrocodone: Negative
- Hydromorphone: Positive
Note: When subscribers get results via EDI (Electronic Data Interchange) and the results for Hydrocodone/Hydromorphone, or Codeine/Morphine, or Oxycodone/Oxymorphone are Negative, the lab may report it as a single item. This will not cause any reporting issues relative to the DOT MIS report as the DOT MIS report modules manages it without a problem.
If you are manually managing results, the Federal Drug Panel should include each drug separately:
- PCP (Phencyclidine)
- Amphetamine (classified as Amphetamines)
- MDMA (or Ecstasy & classified as Amphetamines)
- MDA (classified as Amphetamines)
- Codeine (classified as an Opiate)
- Morphine (classified as an Opiate)
- 6-AM (Heroin) (classified as an Opiate)
- Hydrocodone (classified as an Opiate)
- Hydromorphone (classified as an Opiate)
- Oxycodone (classified as an Opiate)
- Oxymorphone (classified as an Opiate)
The DOT report generator will count each positive according to the requirements when the individual items are classified as Amphetamines or Opiates.
DrugTestNetwork’s online software application, a web-based cloud solution for drug/substance testing result data management and reporting, now integrates with Practice Fusion (visit http://www.practicefusion.com ). This interface further deepens DTNet’s presense as an EMR (Electronic Medical Record) system for drug/substance test result reporting.
DTNet hosts a number of subscribers whose primary business is the provision of services as a reference labs for pain management clinics, rehabilitation clinics and other health care providers. These clinics and other providers who subscribe to Practice Fusion can now get drug/substance test results reported directly into their Practice Fusion account.
How it works:
Practice Fusion [PF] provides a desktop application which acts as the interface to the subscribers database. When the reference lab, as a DTNet subscriber, completes a test result, the application can export the result to an HL7 data file. When the HL7 file is saved to the PF input folder, the PF application pushes it directly to the PF platform. In the current configuration PF only accepts HL7 files that contain a single test result which necessitates the DTNet subscriber to save multiple exported files to their local area network.
DrugTestNetwork’s software, the online application for drug test data management, now integrates with JBR’s LabTrak LIS (Laboratory Information System) (visit http://www.labtrak.com ). The integration deepens the functionality of DTNet as an effective EMR system (Electronic Medical Record) for substance test reporting.
LabTrak was developed by JRB Medical Associates, Inc. It is a laboratory information system offered to medical professionals for the management of patient diagnostics information. The systems are designed for the average physician’s office, pain management clinics, specialty labs and in-house laboratories. It is compliant with CLIA, HIPAA, and all other regulations regarding patient records.
Their lab information system is proprietary software that works with up to four laboratory analyzers at a time and allows medical offices and specialty labs to track and manage diagnostic results with ease.
LabTrak’s HL7 Data Integrates seamlessly with DTNet:
LabTrak exports lab result data via HL7 which is easily uploaded and integrated into DTNet’s data system to facilitate test result reporting through the Client portal modules for your customers: Employers, Doctors, Pain Management Clinics, other Labs, etc.